Kineret®/IL-1ra blocks the IL-1/IL-8 inflammatory cascade during recombinant Panton Valentine Leukocidin-triggered pneumonia but not during S. aureus infection

PLoS One. 2014 Jun 6;9(6):e97546. doi: 10.1371/journal.pone.0097546. eCollection 2014.

Abstract

Objectives: Community-acquired Staphylococcus aureus necrotizing pneumonia is a life-threatening disease. Panton Valentine Leukocidin (PVL) has been associated with necrotizing pneumonia. PVL triggers inflammasome activation in human macrophages leading to IL-1β release. IL-1β activates lung epithelial cells to release IL-8. This study aimed to assess the relevance of this inflammatory cascade in vivo and to test the potential of an IL-1 receptor antagonist (IL-1Ra/Kineret) to decrease inflammation-mediated lung injury.

Methods: We used the sequential instillation of Heat-killed S. aureus and PVL or S. aureus infection to trigger necrotizing pneumonia in rabbits. In these models, we investigated inflammation in the presence or absence of IL-1Ra/Kineret.

Results: We demonstrated that the presence of PVL was associated with IL-1β and IL-8 release in the lung. During PVL-mediated sterile pneumonia, Kineret/IL-1Ra reduced IL-8 production indicating the relevance of the PVL/IL-1/IL-8 cascade in vivo and the potential of Kineret/IL-1Ra to reduce lung inflammation. However, Kineret/IL-1Ra was ineffective in blocking IL-8 production during infection with S. aureus. Furthermore, treatment with Kineret increased the bacterial burden in the lung.

Conclusions: Our data demonstrate PVL-dependent inflammasome activation during S.aureus pneumonia, indicate that IL-1 signaling controls bacterial burden in the lung and suggest that therapy aimed at targeting this pathway might be deleterious during pneumonia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacterial Toxins / toxicity*
  • Exotoxins / toxicity*
  • Inflammasomes / drug effects
  • Inflammasomes / immunology
  • Interleukin 1 Receptor Antagonist Protein / pharmacology*
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-1beta / metabolism*
  • Interleukin-8 / metabolism*
  • Leukocidins / toxicity*
  • Macrophages / drug effects
  • Macrophages / immunology
  • Pneumonia, Staphylococcal / drug therapy*
  • Pneumonia, Staphylococcal / etiology
  • Pneumonia, Staphylococcal / metabolism
  • Rabbits

Substances

  • Bacterial Toxins
  • Exotoxins
  • Inflammasomes
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Interleukin-8
  • Leukocidins
  • Panton-Valentine leukocidin

Grants and funding

This work was supported by a FINOVI young investigator grant to TH. SOBI had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.